Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine‐based therapy with or without bevacizumab by Pant, Shubham et al.
Baseline Serum Albumin Is a Predictive Biomarker for Patients
With Advanced Pancreatic Cancer Treated With Bevacizumab
A Pooled Analysis of 7 Prospective Trials of Gemcitabine-Based Therapy
With or Without Bevacizumab
Shubham Pant, MD1; Ludmila K. Martin, MD2; Susan Geyer, PhD3; Lai Wei, PhD3; Katherine Van Loon, MD4;
Nilli Sommovilla, MD5; Mark Zalupski, MD6; Renuka Iyer, MD7; David Fogelman, MD8; Andrew H. Ko, MD4; and
Tanios Bekaii-Saab, MD2
BACKGROUND: Phase 3 studies of bevacizumab in patients with advanced pancreatic cancer (APCA) demonstrated no improve-
ment in outcome. To the authors’ knowledge, no validated predictive biomarkers for bevacizumab exist, although emerging data
suggest that subsets of patients with APCA may benefit from treatment with bevacizumab. The authors evaluated baseline serum
albumin (b-alb) as a predictive biomarker in a pooled analysis from 7 prospective clinical trials of gemcitabine-based therapy with
or without bevacizumab. METHODS: Data were collected from individual databases from 7 prospective clinical trials. Patients were
grouped by exposure to bevacizumab and by b-alb level ( 3.4 g/L or<3.4 g/dL). Overall survival (OS), time to disease progres-
sion (TTP), overall response rate, and disease control rate (overall response rate plus stable disease lasting 16 weeks) were com-
pared between groups. Univariate and multivariable analyses of prognostic factors were performed. RESULTS: A total of 264
patients were included. The median age was 59 years (range, 31 years-85 years) and all patients had stage IV disease per TNM
staging. Normal b-alb was associated with significantly improved median OS (10.2 months vs 4.1 months; P5.0001), median TTP
(6.2 months vs 3.7 months; P50.0488), and disease control rate (71% vs 46%; P5.007) for patients receiving bevacizumab, but
not for those treated without bevacizumab. Multivariable analysis revealed a significant influence of normal b-alb on OS
(P5.0008) and TTP (P5.033). CONCLUSIONS: Patients with APCA with normal b-alb derive benefit from treatment with bevacizu-
mab. Future prospective investigations of bevacizumab in patients with APCA should consider selecting patients with normal b-alb
to maximize potential benefit. Cancer 2014;120:1780–6. VC 2014 American Cancer Society.
KEYWORDS: pancreatic cancer, albumin, bevacizumab, predictive biomarker.
INTRODUCTION
Pancreatic cancer (PCA) remains the fourth leading cause of cancer death in United States.1 The prognosis for patients
with advanced disease is poor, with the majority surviving< 6 months with standard gemcitabine therapy.2 Although a 4-
month survival benefit was recently reported with the combination of 5-fluorouracil, leucovorin, irinotecan, and oxalipla-
tin (FOLFIRINOX),3 the toxicities of this regimen prohibit its use in the majority of patients with metastatic disease.
Recently presented data indicate a less impressive but significant 1.8-month survival benefit from the addition of nab-
paclitaxel to gemcitabine in patients with metastatic PCA.4 Despite these advances, there is a continuous need to further
improve survival through the investigation of molecularly targeted agents.
Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody that binds to vascular endothe-
lial growth factor (VEGF) and prevents it from interacting with its receptors (VEGFR).5 Although preclinical data have sug-
gested VEGF as a promising therapeutic target in PCA,6-8 3 phase 3 trials of gemcitabine plus antiangiogenic therapy with
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bevacizumab9,10 or the VEGF receptor tyrosine kinase in-
hibitor axitinib11 failed to reach their primary endpoint of
overall survival (OS) in unselected patients.
Efforts have been made to identify predictive bio-
markers for bevacizumab efficacy in patients with PCA;
however, to the best of our knowledge none have been
validated to date. Exploratory analyses from the AViTA
trial9 suggested that a subset of patients with elevated
VEGFA or VEGFR2 levels may benefit from bevacizu-
mab.12 These results suggest that angiogenesis remains an
interesting therapeutic target in patients with PCA and
further investigation is needed to identify subsets of
patients who may benefit from this treatment approach.
Pharmacokinetic analyses of bevacizumab have shown
that patients with a low baseline serum albumin (b-alb) expe-
rience a 15% to 20% increase in the rate of bevacizumab
clearance.13Although the clinical implications of this phe-
nomenon are not well understood, exposure to lower thera-
peutic levels of bevacizumab could adversely impact clinical
outcome. We recently reported a significant improvement in
OS and time to disease progression (TTP) for patients with
advanced PCA (APCA) and a b-alb level 3.4 g/dL who
were treated on a phase 2 study of gemcitabine, infusional 5-
fluorouracil, and bevacizumab.16 Our data suggested that this
subset of patients may derive significant benefit from bevaci-
zumab, and that the potential predictive value of b-alb should
be further investigated in patients with APCA.
To further investigate the role of b-alb as a bio-
marker for bevacizumab efficacy in patients with APCA,
we evaluated clinical outcomes according to b-alb using
pooled data from 7 prospective studies of gemcitabine-
based therapy with or without bevacizumab.
MATERIALS AND METHODS
Study Design
The current study was an analysis of pooled data from 7
prospective, single-arm, phase 1/2 or phase 2 trials of
gemcitabine-based regimens conducted at the Ohio State
University, University of Michigan, Roswell Park Cancer
Institute, University of California at San Francisco, The
University of Texas MD Anderson Cancer Center, and
the University of Oklahoma (Table 1).16-22 Raw data
were collected from each clinical trial database before
pooled analysis, including patient demographics, known
prognostic factors (including disease stage, Eastern Coop-
erative Oncology Group [ECOG] performance status,
baseline CA 19-9, and change in CA 19-9 with treat-
ment), b-alb level (< 3.4 g/dL or 3.4 g/dL) measured
within 7 days of treatment initiation, and clinical out-
come measures (including objective response rate [ORR],
disease control rate [DCR; ORR plus stable disease
lasting 16 weeks], TTP, and OS) for all patients.
Patients were grouped according to treatment with bevaci-
zumab (group 1) or no bevacizumab (group 2) and clini-
cal outcomes of interest were assessed within each group
and for all patients according to b-alb. The primary objec-
tives of the current study were to determine the predictive
and/or prognostic value of b-alb in patients with APCA
and specifically those treated with bevacizumab.
Eligibility
Studies selected for pooled analysis were required to
include patients with APCA proven by cytology or histol-
ogy. To limit potential confounding factors for clinical
outcomes, studies for pooled analysis (both bevacizumab
and nonbevacizumab studies) had strict inclusion criteria,
including the availability of b-alb data. Patients included
in the raw database were required to have stage IV disease,
an ECOG performance status of 0 to 1, no prior treat-
ment for metastatic disease, and a b-alb value collected
within 7 days of treatment initiation. Treatment was
required to be gemcitabine-based for inclusion in the cur-
rent analyses and would include bevacizumab at a dose of
5 mg/kg/week with the various dosing schedules. All stud-
ies included were approved by the respective Institutional
Review Boards at each institution.
TABLE 1. Studies Included in the Pooled Analysis
Study Phase
No. of
Patients Chemotherapy Median TTP/PFS Median OS
Ko 200617 2 51 FDR gemcitabine1 cisplatin 3.9 mo (TTP) 7.1 mo
Ko 200818 2 52 FDR gemcitabine1 cisplatin1bevacizumab 6.6 mo (TTP) 8.2 mo
Javle 200919 2 50 Gemcitabine1 capecitabine1 bevacizumab 5.8 mo (PFS) 4.8 mo
Fogelman 201120 2 50 FDR gemcitabine1oxaliplatin1bevacizumab 4.9 mo (PFS) 11.9 mo
Hill 201121 1 21 FDR gemcitabine1 capecitabine1docetaxel 5.8 mo (PFS) 7.4 mo
Martin 201216 2 42 FDR gemcitabine1 infusional 5-FU1bevacizumab 5.9 mo (PFS) 7.4 mo
Ko 201222 1 45 FDR gemcitabine1 capecitabine 5.5 mo (TTP) 9.8 mo
Abbreviations: 5-FU, 5-fluorouracil; FDR, fixed dose rate; OS, overall survival; PFS, progression-free survival; TTP, time to disease progression.
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Statistical Analysis
Clinical outcomes were defined as follows: OS was defined
as the time from first treatment until death from any cause,
TTP was defined as the time from first treatment until dis-
ease progression, ORR was defined as the percentage of
patients achieving a complete or partial response by
Response Evaluation Criteria In Solid Tumors (RECIST)
criteria used in each individual study, and DCRwas defined
as the percentage of patients achieving an objective response
or stable disease for 16 weeks. Patients who were lost to
follow-up or who were still alive were censored at the date of
their last visit. Patient characteristics were summarized using
descriptive statistics and graphical analyses as part of explor-
atory data analyses. Factors were compared between groups
of interest (eg, protocol treatment, bevacizumab vs not, low
b-alb vs not) using 2-sample Student t tests for continuous
measures and chi-square tests for categorical markers or their
nonparametric equivalents in the cases in which assump-
tions did not hold. The clinical outcomes described above
were compared between groups of interest. For dichoto-
mous outcomes such as ORR and DCR, univariate and
multivariable logistic regression models were used to evalu-
ate differences. Goodness of fit for logistic regressionmodels
was assessed based on the methods of Hosmer and Leme-
show.23 For TTP andOS, univariate and multivariable Cox
regression models24 were used to assess the prognostic influ-
ence of clinical factors. Proportional hazards were tested
using the methods of Therneau and Grambsch.25 Kaplan-
Meier26 methods were also used to assess differences in these
distributions graphically and log-rank tests27 were used to
quantitatively evaluate differences in survival distributions.
Statistical significance was declared for P values< .05.
RESULTS
Characteristics of Included Clinical Trials
Seven prospective clinical trials were included in these
analyses (Table 1).16-22 All trials involved gemcitabine-
based therapy, and 4 trials included bevacizumab. Only 2
of these trials met their primary endpoint.16,19 All studies
included patients with APCA. Patient characteristics by
study included in these analyses demonstrated some dif-
ferences in clinical factors, including ECOG performance
status distribution (P5 .0003), sex distribution
(P5 .03), and percentage of patients with a b-alb lev-
el< 3.4 g/dL (P5 .014). Median age and CA 19-9 level
were found to be similar among the studies.
Patient Characteristics
A total of 311 patients were identified in the pooled data-
base. Forty-seven patients were excluded for the following
reasons: stage III disease (28 patients), ECOG perform-
ance status of 2 (11 patients), prior therapy for advanced
disease (1 patient), or lack of an available b-alb value
(7 patients). A total of 264 patients were therefore
included in the raw data analysis. Patient characteristics
are outlined in Table 2, and were balanced between
groups 1 and 2 (bevacizumab vs no bevacizumab, respec-
tively). Continuous measures of b-alb were found to be
similar in both treatment groups (measure 1: 3.8 g/dL;
and measure 2: 3.8 g/dL [P5 .7]). The percentage of
patients with low b-alb (< 3.4 g/dL) was also similar in
groups 1 and 2 (21% vs 16%; P5 .47) (Table 2).
Clinical Outcomes According to b-alb Level
When combining all patients, a b-alb level 3.4 g/dL was
found to be associated with significantly improved OS
(median, 9.6 months vs 4.9 months; hazards ratio [HR],
0.8 [P5 .0005]), TTP (median 5.8 months vs 3.4
months; HR, 0.69 [P5 .04]), and ORR and DCR
(ORR: 24% vs 10% [P5 .043]; DCR: 65% vs 43%
[P5 .007]). Using multivariable analysis adjusted for
known clinical prognostic factors and receipt of bevacizu-
mab, b-alb remained a significant independent predictor
of OS (P5 .0009) (Fig. 1 Top), TTP (P5 .04) (Fig. 1
Bottom), and DCR (P5 .008) and was found to have
borderline significance for ORR (P5 .053).
In patients specifically treated with bevacizumab, a
b-alb level 3.4 g/dL was found to be associated with a
significant improvement in OS (median, 10.2 months vs
4.1 months; HR, 2.1 [P5 .0001]) (Fig. 2 Top), TTP






No. (%) 167 97
Median age (range), y 60 (31-85) 58 (33-78) .17
Sex .96
Male 78 (47) 47 (48)
Female 88 (53) 50 (52)
ECOG performance status
0 72 (43) 43 (44) .64
1 92 (55) 47 (48)
0 or 1 (not specified) 3 (2) 7 (8)
Stage
IV 136 (100) 97 (100) 1.00
CA 19-9 23 ULN
Yes 122 (73) 76 (78) .46
No 44 (26) 21 (22)
Not available 1 (1) 0 (0)
Baseline albumin, g/dL
3.4 132 (75) 81 (83) .15
<3.4 35 (25) 16 (17)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ULN, upper
limit of normal.
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(median 6.2 months vs 3.7 months; HR, 1.8 [P5 0.0488])
(Fig. 2 Bottom), and DCR (71% vs 46%; P5 .007), with
a trend toward improved ORR (28% vs 11%; P5 .051).
Multivariable analysis for OS and TTP revealed b-alb
(P5 .0004 and P5 .049, respectively), ECOG perform-
ance status (P5 .03 and P5 .0007, respectively), and sex
(P5 .02 and P5 .017, respectively) to be independent
predictors of OS and TTP.
For patients who did not receive bevacizumab, there
were no significant differences noted with regard to OS
(median, 8.9 months vs 5.1 months; HR, 1.26 [P5 .43]),
TTP (median, 4.7 months vs 3.4 months; HR, 1.54
[P5 .17]), ORR (18% vs 6%; P5 .28), or DCR (56% vs
44%; P5 .36) according to b-alb (Table 3).
DISCUSSION
APCA has proven to be a relatively chemoresistant disease
and new approaches with targeted therapies are needed. A
large volume of preclinical evidence has implicated angio-
genesis, and VEGF in particular, as relevant and promising
therapeutic targets in patients with APCA6; however, phase
3 studies of antiangiogenic agents including bevacizumab
Figure 1. .Using multivariable analysis adjusted for known
clinical prognostic factors and receipt of bevacizumab, base-
line serum albumin (b-alb) remained a significant independ-
ent predictor of (Top) overall survival (OS) (P5.0009) and
(Bottom) time to disease progression (TTP) (P5.04). ULN
indicates upper limit of normal; ECOG PS, Eastern Coopera-
tive Oncology Group performance status; HR, hazards ratio;
95% CI, 95% confidence interval.
Figure 2. In patients specifically treated with bevacizumab, a
baseline serum albumin (b-alb) level3.4 g/dL was found to
be associated with a significant improvement in (Top) overall
survival (median, 10.2 months vs 4.1 months; hazards ratio, 2.1
[P5.0001]) and (Bottom) time to disease progression (median
6.2 months vs 3.7 months; hazards ratio, 1.8 [P50.0488]).
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have had negative results in unselected patients.9-11 Increas-
ing evidence suggests that proper patient selection through
the identification and use of predictive biomarkers may
maximize the efficacy of targeted anticancer therapies. To
the best of our knowledge, no such predictive biomarkers
for bevacizumab have been validated in any advanced
malignancy, although recent exploratory data have sug-
gested baseline VEGFA levels may correlate with clinical
outcomes.12 Our previous investigations indicated that a b-
alb level 3.4 g/dL may be predictive of bevacizumab effi-
cacy and warranted further investigation.
The results of the current study suggest a predictive
role for b-alb in patients with APCA receiving bevacizu-
mab, independent of other prognostic factors. Our analy-
ses revealed that b-alb significantly influenced clinical
outcome in those patients with regimens that included
bevacizumab, but did not appear to impact survival out-
comes in those patients who did not receive bevacizumab.
In addition, in our analysis of patients with APCA who
were treated with bevacizumab, a b-alb level< 3.4 g/dL
was found to remain a strong independent predictor of in-
ferior outcomes for patients with APCA receiving bevaci-
zumab, after adjusting for other clinical covariates. The
current study data suggest that b-alb has a prognostic role
in patients with APCA who are treated with bevacizumab,
and is a potential predictive marker for survival outcomes
in those patients despite combination treatments with
other agents. The literature suggests that this finding may
be confounded by the association between low b-alb with
other factors associated with poor prognosis, including
older age, poor ECOG performance status, more aggres-
sive or advanced disease, poor nutritional status, or he-
patic dysfunction. In the analysis cohort in the current
study, b-alb proved to be significantly associated with
clinical outcomes even when we adjusted for ECOG per-
formance status and patient age. Therefore, despite the
previously reported prognostic significance of b-alb
regardless of treatment, the results of the current study
indicate a novel use for b-alb as a predictive biomarker in
patients with APCA receiving bevacizumab. Furthermore,
to the best of our knowledge, the current study is the first
report of the predictive or prognostic value of b-alb specif-
ically in patients with APCA.
The predictive value of b-alb may be explained by a
pharmacokinetic description of bevacizumab. A small ex-
ploratory analysis suggested a 15% increased rate of beva-
cizumab clearance for patients with colon cancer with
lower b-alb who were treated with bevacizumab. This was
independent of prognostic variables such as age, sex, tu-
mor stage, and ECOG performance status, all of which
were found to have no impact on bevacizumab clear-
ance.13 A larger study using pooled data from 8 clinical
trials found that patients with a b-alb level 2.9 g/dL
experienced a 20% increase in their rate of bevacizumab
clearance.14
The interpretation of the findings of the current
study is limited by their retrospective nature and the rela-
tively small sample size of the group not treated with beva-
cizumab, although these results were strengthened by the
choice of study design. Unlike a meta-analysis, a pooled
analysis includes individual patient data that were pro-
spectively collected within the context of a clinical trial,
TABLE 3. Clinical Outcomes According to Baseline Albumin (N5264)
Group
Outcome (95% CI)
Median OS, Months Median TTP, Months ORR, % DCR, %a
All patients (N5264)
b-alb 3.4 g/dL 9.6 (8.5-11.1) 5.8 (5.1-6.6) 24 (18-30) 65 (58-71)
b-alb <3.4 g/dL 4.9 (3.4-8.0) 3.4 (2.2-7.3) 10 (3-21) 43 (29-58)
Pb .0005 .04 .043 .007
Group 1 (B) (N5167)
b-alb 3.4 g/dL 10.2 (8.6-11.9) 6.2 (5.6-7.6) 28 (21-37) 71 (62-78)
b-alb <3.4 g/dL 4.1 (2.8-8.4) 3.7 (2.0-7.6) 11 (3-27) 46 (29-63)
Pb .0001 .0488 .051 .007
Group 2 (no B) (N597)
b-alb 3.4 g/dL 8.9 (7.8-11.1) 4.7 (3.6-6.4) 18 (10-28) 56 (45-67)
b-alb <3.4 g/dL 5.1 (3.8-16.0) 3.4 (1.8-NA) 6 (0.2-30) 44 (20-70)
Pb .43 .17 .28 .36
Abbreviations: 95% CI, 95% confidence interval; B, bevacizumab, b-alb, baseline serum albumin; DCR, disease control rate; NA, not available; ORR, overall
response rate; OS, overall survival; TTP, time to disease progression.
a DCR indicates partial response and stable disease with a duration of 16 weeks.
b Bold type indicates statistical significance.
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which improves the strength and statistical significance of
the final results. An additional potential weakness of the
current study is that relatively small numbers of patients
had low b-alb levels. However, the overall results are
strengthened by the relatively large sample size of the
study population enrolled at multiple participating insti-
tutions, including a meaningful control population of
patients treated without bevacizumab. Finally, although
there was some heterogeneity with regard to treatment
and prognostic factors among the 7 individual studies
included, we demonstrated the absence of a significant
difference in these prognostic factors between groups in
our pooled data set.
In conclusion, we identified b-alb as a potential pre-
dictive biomarker for the efficacy of bevacizumab in
patients with APCA. In addition, the results of the current
study suggest a likely prognostic role for b-alb in patients
with APCA who are being treated with bevacizumab,
regardless of other agents being used in combination with
bevacizumab. Future prospective investigations of bevaci-
zumab in patients with APCA should continue and
should consider selecting patients with normal b-alb to
maximize potential benefit. Finally, although the current
study focused on patients with APCA, the findings have
potential applicability to other advanced malignancies in
which bevacizumab is currently under study or represents
a standard of care.
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